DOCSLIB.ORG

Management of Thalassaemia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Management of Thalassaemia ___________________________________________________MANAGEMENT OF THALASSAEMIA REP ORT MANAGEMENT OF THALASSAEMIA HEALTH TECHNOLOGY ASSESSMENT UNIT MEDICAL DEVELOPMENT DIVISION health MINISTRY OF HEALTH MALAYSIA MOH/PAK/77.03 (TR) i ___________________________________________________MANAGEMENT OF THALASSAEMIA EXECUTIVE SUMMARY 1. BACKGROUND Thalassaemias and Sickle cell disorder, are the commonest human inherited haemoglobin disorders that can be treated effectively, and also prevented at community level. Thalassaemia is the commonest single gene disorder in Malaysia and a paradigm of monogenetic diseases. In 1995, it was estimated that about 8,000 persons were afflicted with HbE beta Thalassaemia, and 8,000 with Homozygous beta-Thalassaemia, about 40% of whom were dependent on regular blood transfusions for survival (Kaur, 1995). In addition, the carrier rate for beta Thalassaemia and HbE is estimated to be 3-5%. Besides blood transfusion, another curative option is the use of haemopoietic stem cell transplantation. In Malaysia, it is currently being offered to potential patients with suitable donors at two centres, namely, University Malaya Medical Centre and the Paediatrics Institute, Kuala Lumpur Hospital. 2 OBJECTIVE To determine the safety, effectiveness, cost implications as well as ethical, legal and social implications of management of Thalassaemia. 3. SCOPE This assessment does not include diagnosis of Thalassaemia, as well as antenatal screening for Thalassaemia that has already been assessed previously under antenatal screening. 4. RESULTS There is sufficient evidence that a screening and prevention programme is effective for the control of β-thalassaemia trait. The options for effective screening include screening of 15-16 year old school students, pre-marital screening, and screening of relatives of known carriers. Screening tests include MCH and osmotic fragility test. The complications of Thalassaemia include Hepatitis B and Hepatitis C, cardiac complications like heart failure, short stature, pubertal delay, and osteoporosis. Other less common complications include diabetes mellitus. With respect to blood transfusion, there is sufficient evidence to conclude that leukocyte reduced red cells, produced either in the blood bank or using bed-side filters, are effective in reducing transfusions reactions, the better the filter, the greater the reduction in transfusion reactions. The use of neocytes for transfusion can decrease blood requirement, but is costly. For the treatment of Thalassaemia by chelation therapy, there is sufficient evidence that Desferrioxamine and Deferiprone are effective in preventing or improving serious complications of the disease. There is sufficient evidence that sibling donor bone marrow transplantation is safe and effective, and more cost effective compared to blood transfusion therapy. There is also evidence of effectiveness of bone marrow transplantation from unrelated and alternative donors, cord blood transplantation and peripheral blood stem cell transplantation. Modulators of fetal hemoglobin synthesis like Hydroxyurea, Butyrates, 5 Azacytidine and Erythropoietin is still largely experimental and cannot replace the need for regular blood transfusions and regular chelation therapy. Gene therapy to replace bone marrow transplant seems to be possible. There is insufficient evidence on the effectiveness of other treatment modalities like nutrition support and vitamins. 5. RECOMMENDATION It is recommended that a screening and prevention programme for the control of β-thalassaemia trait be instituted. Screening of school students and screening of relatives of known carriers should be carried out. Pre-marital and prenatal screening services should be offered for those who request for it. ii ___________________________________________________MANAGEMENT OF THALASSAEMIA Thalassaemic children on blood transfusion should receive leukocyte-reduced red cells for. All blood should be screened for ABO and Rh (D) compatibility, while Rh (C and E) and Kell is not recommended because of high cost involved. For Chelation therapy, it is recommended that Desferrioxamine and Deferiprone be used to prevent or improve serious complications of the Thalassaemia. Bone Marrow Transplantation should be offered to patients as soon as possible especially if there is a HLA compatible sibling/ family member. Bone marrow transplantation from unrelated and alternative donors, cord blood transplantation and peripheral blood stem cell transplantation services can also be offered where indicated. There is insufficient evidence to recommend other treatment modalities. iii ___________________________________________________MANAGEMENT OF THALASSAEMIA EXPERT COMMITTEE 1. Dr Wong Swee Lan Cahirman Head & Consultant Paediatrician Institute of Paediatric Kuala Lumpur Hospital 2. Dr Ng Hoong Phak Consultant Paediatrician Sarawak Umum Hospital 3. Dr Tam Pui Ying Consultant Paediatrician Sultanah Aminah Hospital 4. Dr Hung Liang Choo Consultant Paediatrician Institute of Paediatric Kuala Lumpur Hospital 5. Dr Zulaiha Muda Consultant Paediatrician Institute of Paediatric Kuala Lumpur Hospital 6. Dr Safiah Bahrin Principal Assistant Director Family Health Development Divison 7. Dr Balveer Kaur Consultant Paediatric Haematology Ipoh Hospital 8. Prof Dr Rahman Jamal Consultant Paediatrician University Kebangsaan Malaysia Hospital 9. Prof Dr Thong Meow Keong Consultant Paediatrician University Malaya Medical Centre 10 Prof Dr E George Unit Haematology University Putra Malaysia Project Coordinators 1. Dr S Sivalal Head, Health Technology Assessment Unit Deputy Director Medical Development Division Ministry of Health Malaysia 2. Ms Sin Lian Thye Nursing Officer Health Technology Assessment Unit Ministry of Health Malaysia iv ___________________________________________________MANAGEMENT OF THALASSAEMIA TABLE OF CONTENTS EXECUTIVE SUMMARY i EXPERT COMMITTEE iv TABLE OF CONTENTS v 1 BACKGROUND 1 2 OBJECTIVE 1 3 SCOPE 1 4 TECHNICAL FEATURES 1 4.1 Screening Program 1 4.2 Treatment 2 4.2.1 Blood transfusion 2 4.2.2 Chelation therapy 3 4.2.3. Haemopoitic stem cell transplantation 4 4.2.4. Other treatment modalities 4 (i) Augmentation of Fetal Hemoglobin Synthesis 4 (a) Hydroxyurea 4 (b) 5 Azacytidine 4 (c) Butyrates 4 (d) Erythropoietin 5 (e) Combination Agents 5 (ii) Gene Therapy 5 (iii) Others 5 5 METHODOLOGY 5 6 RESULTS & DISCUSSION 5 6.1 Screening and Prevention of Thalassaemia 5 6.1.1 Effectiveness 6 6.1.2 Target population for screening 7 (i) School students 7 (ii) Premarital screening programme 7 (iii) Inductive or cascade screening programme 7 6.1.3 Cost effectiveness - Thalassaemia prevention programme 7 6.1.4 Laboratory tests for Thalasseamia screening 8 6.1.5 Ethical, legal and social issues in genetic screening 8 Ethical issues 8 Legal issues 8 Social issues 9 Genetic Counselling 9 CONCLUSION 9 6.2 Complications of Thalasssemia 10 6.2.1 Hepatitis C, hepatitis B and HIV 10 6.2.2 Cardiac complications 10 6.2.3 Short stature in patients with Thalassaemia 10 6.2.4 Pubertal delay in patients with Thalassaemia 11 6.2.5 Diabetes Mellitus in patients with Thalassaemia 11 6.2.6 Osteoporosis in Thalassaemia patients 11 6.3 Treatment 12 6.3.1 Blood transfusion 12 (i) Type of Blood Products. 12 v ___________________________________________________MANAGEMENT OF THALASSAEMIA (a) Leukocyte Reduced Red Cells 12 (b) Neocytes 12 (ii) Transfusion regimes 13 (a) Pretransfusion Haemoglobin (Hb) Level 13 (b) Transfusion interval 13 (iii) Compatibility testing 13 (iv) Cost 14 6.3.2 Chelation Therapy 14 (i) Safety 14 (ii) Effectiveness 15 The Impact of Iron-Chelating Therapy on 15 Cardiac Disease and Survival The impact of iron-chelating therapy in 15 liver disease Impact of iron-chelating therapy on 15 endocrine function and growth Impact on quality of life 16 Impact on Bone Marrow Transplantation 16 patients Compliance with Deferoxamine and 16 alternatives to subcutaneous infusion (iii) Cost effectiveness 17 6.3.3 Oral Deferioximine(L1) 17 (i) Safety 17 (ii) Dose and route of administration 17 iii) Effectiveness 17 CONCLUSIONS 18 6.3.4 Transplantation 18 (i) Safety 18 (ii) Effectiveness 18 Sibling donor bone marrow transplantation 18 Bone marrow transplantation from 20 unrelated donors and alternative donors Cord blood transplantation 20 Peripheral blood stem cell transplantation 20 CONCLUSION 21 63.5 Other treatment modalities 21 (i) Augmentation of Fetal Hemoglobin 21 Synthesis (a) Hydroxyurea 21 (b) 5 Azacytidine 21 (c) Butyrates 21 (d) Erythropoietin 21 (e) Combination Agents 21 (f) Other agents 22 (ii) Gene Therapy 22 (iii) Nutrition, Vitamins Support 22 (iv) Psychological therapy 22 CONCLUSION 22 vi ___________________________________________________MANAGEMENT OF THALASSAEMIA 7 CONCLUSION 23 8 RECOMMENDATION 24 8.1 Prevention and screening programme 24 8.2 Treatment 24 8.2.1 Blood Transfusion 24 8.2.2 Chelataion therapy 24 8.2.3 Bone Marrow transplantation 24 8.2.4 Other treatment modalities 24 9 REFERNCES 25 EVIDENCE TABLE 38 LIST OF TABLE Table 1 : Bone Marrow Transplantation inpatients with Thalassaemia 18 Table 2: Reported Transplants for Thalassaemia and Probabilities of 18 Survival and Disease Free Survival in Various International Centres Table 3 : Comparison of survival rates between BMT and conventional 19 therapy at the age of 25 years Appendix 1 METHODOLOGY 128 . 1 Screening and Prevention 2 Complications 3 Treatment 3.1 Blood transfusion 3.2 Chelation Therapy (i) Desferrioxamine (ii) Deperine (L1) 3.3 Haemopoietic Stem Cell Transplantation
Load more

Recommended publications
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • CHEMDNER-Patents: Chemical Entity Annotation Manual
    CHEMDNER-patents: Chemical Entity annotation manual Version 2.0 (May 2015) This document describes the annotation guidelines used for the construction of the annotations chemical mentions (CEM – Chemical Entity Mention) of the CHEMDNER-patents corpus. These annotation guidelines were generated based on the CHEMDNER 2013 task exclusively focused on chemical entities extracted from papers. Thus, annotation guidelines were adapted to mine patents with a stronger focus on identifying any wide definition of chemical terms rather than in obtaining highly refined chemical mentions that can be univoquely translated into a chemical structure. The reason for this subtle refinement resides in the fact that patents contain very wide, general chemical mentions to describe the different substituents of the general Markush formula. Discarding this kind of mentions would prevent future applications (e.g. deconvolution and interpretation of Markush formula) of the CHEMDNER-patents corpus. However, no attempt is made to establish Markush structure relation: establishing meaningful correlations between the Markush formula and substituents. Thus, two related CEMs that are clearly separated as different entities in the text will be annotated as two different CEMs; although the meaning of one of them can be linked to the other one. This guide provides the basic details of the CEM task and the conventions that should be followed during the corpus construction process. The annotation guidelines were refined after iterative cycles of annotations of sample documents based on direct suggestions made by the curators as well as through the observation of inconsistencies detected when comparing the results provided by different curators. Some participating teams provided feedback to improve the documentation after the release of the first sample set prepared for the CHEMDNER 2013 task.
    [Show full text]
  • Mcleod Neuroacanthocytosis Syndrome
    NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993- 2017. McLeod Neuroacanthocytosis Syndrome Hans H Jung, MD Department of Neurology University Hospital Zurich Zurich, Switzerland [email protected] Adrian Danek, MD Neurologische Klinik Ludwig-Maximilians-Universität München, Germany ed.uml@kenad Ruth H Walker, MD, MBBS, PhD Department of Neurology Veterans Affairs Medical Center Bronx, New York [email protected] Beat M Frey, MD Blood Transfusion Service Swiss Red Cross Schlieren/Zürich, Switzerland [email protected] Christoph Gassner, PhD Blood Transfusion Service Swiss Red Cross Schlieren/Zürich, Switzerland [email protected] Initial Posting: December 3, 2004; Last Update: May 17, 2012. Summary Clinical characteristics. McLeod neuroacanthocytosis syndrome (designated as MLS throughout this review) is a multisystem disorder with central nervous system (CNS), neuromuscular, and hematologic manifestations in males. CNS manifestations are a neurodegenerative basal ganglia disease including (1) movement disorders, (2) cognitive alterations, and (3) psychiatric symptoms. Neuromuscular manifestations include a (mostly subclinical) sensorimotor axonopathy and muscle weakness or atrophy of different degrees. Hematologically, MLS is defined as a specific blood group phenotype (named after the first proband, Hugh McLeod) that results from absent expression of the Kx erythrocyte antigen and weakened expression of Kell blood group antigens. The hematologic manifestations are red blood cell acanthocytosis and compensated hemolysis. Allo-antibodies in the Kell and Kx blood group system can cause strong reactions to transfusions of incompatible blood and severe anemia in newborns of Kell-negative mothers.
    [Show full text]
  • Comparative Study of Deferiprone Versus Deferiprone with Deferasirox
    BANGLADESH J CHILD HEALTH 2019; VOL 43 (3) : 152-156 Comparative study of Deferiprone versus Deferiprone with Deferasirox as iron chelation therapy in Thalassemic children SYEDA JARKA JAHIR1, SAYEEDA ANWAR2, AKM AMIRUL MORSHED3, AFIQUL ISLAM4, KABIRUL ISLAM5 Abstract Background: Combination therapy of Deferiprone (DFP) with Deferasirox (DFX) is an efficacious and safe modality to reduce serum ferritin in multi-transfused children with thalassemia. Objectives: To compare the efficacy of Deferiprone versus Deferiprone with Deferasirox as iron chelation therapy of transfusion dependent thalassemia children. Materials and Methods: A non-randomized control clinical trial was done in department of Pediatric Hematology and Oncology, Dhaka Medical College Hospital and Bangladesh Thalassemia Hospital in Dhaka during the period of October 2016 to September 2017. Thirty children with transfusion dependent thalassemia major between 3 to 12 years of age were included in each group in this study. Children with thalassemia minor, after splenectomy, with comorbidities and on other iron chelation therapy were excluded from this study. Results: Among total enrolled 60 cases in this study, initial mean serum ferritin level was 3397.48 ± 774.48 ng/ml in DFP-monotherapy group and 3413.70 ± 1114.05ng/ ml in DFP-DFX combination group. Mean serum ferritin level at 6thmonth was found 2730.63 ± 839.91ng/ml in DFP-monotherapy group and 1654.20 ± 934.90 ng/ml in DFP-DFX-combination group which shows rapid reduction of serum ferritin level in DFP-DFX-combination group. 12 (40.0%) patients had arthralgia in DFP- monotherapy group and 5(16.7%) patients had vomiting in DFP-DFX-combination group.
    [Show full text]
  • MEDICATION GUIDE FERRIPROX (Feh' Ri Prox) (Deferiprone) Oral
    MEDICATION GUIDE FERRIPROX® (Feh’ ri prox) (deferiprone) oral solution What is the most important information I should know about FERRIPROX? FERRIPROX can cause serious side effects, including a very low white blood cell count in your blood. One type of white blood cell that is important for fighting infections is called a neutrophil. If your neutrophil count is low (neutropenia), you may be at risk of developing a serious infection that can lead to death. Neutropenia is common with FERRIPROX and can become severe in some people. Severe neutropenia is known as agranulocytosis. If you develop agranulocytosis, you will be at risk of developing serious infections that can lead to death. Your healthcare provider should do a blood test before you start FERRIPROX and weekly during treatment to check your neutrophil count. If you develop neutropenia, your healthcare provider should check your blood counts every day until your white blood cell count improves. Stop taking FERRIPROX and get medical help right away if you develop any of these symptoms of infection: •fever • sore throat or mouth sores • flu-like symptoms • chills and severe shaking. See “What are the possible side effects of FERRIPROX?” for more information about side effects. What is FERRIPROX? FERRIPROX is a prescription medicine used to treat people with thalassemia syndromes who have iron overload from blood transfusions, when current iron removal (chelation) therapy does not work well enough. It is not known if FERRIPROX is safe and effective: • to treat iron overload due to blood transfusions in people with any other type of anemia that is long lasting (chronic) • in children Who should not take FERRIPROX? Do not take FERRIPROX if you are allergic to deferiprone or any of the ingredients in FERRIPROX.
    [Show full text]
  • Immuno 2014 No. 1
    Journal of Blood Group Serology and Molecular Genetics VOLUME 30, N UMBER 1, 2014 Immunohematology Journal of Blood Group Serology and Molecular Genetics Volume 30, Number 1, 2014 CONTENTS R EPORT 1 Indirect antiglobulin test-crossmatch using low-ionic-strength saline–albumin enhancement medium and reduced incubation time: effectiveness in the detection of most clinically significant antibodies and impact on blood utilization C.L. Dinardo, S.L. Bonifácio, and A. Mendrone, Jr. R EV I EW 6 Raph blood group system M. Hayes R EPORT 11 I-int phenotype among three individuals of a Parsi community from Mumbai, India S.R. Joshi C A SE R EPORT 14 Evans syndrome in a pediatric liver transplant recipient with an autoantibody with apparent specificity for the KEL4 (Kpb) antigen S.A. Koepsell, K. Burright-Hittner, and J.D. Landmark R EV I EW 18 JMH blood group system: a review S.T. Johnson R EPORT 24 Demonstration of IgG subclass (IgG1 and IgG3) in patients with positive direct antiglobulin tests A. Singh, A. Solanki, and R. Chaudhary I N M EMOR ia M 28 George Garratty, 1935–2014 Patricia A. Arndt and Regina M. Leger 30 A NNOUNCEMENTS 34 A DVERT I SEMENTS 39 I NSTRUCT I ONS FOR A UTHORS E D I TOR - I N -C H I EF E D I TOR ia L B OA RD Sandra Nance, MS, MT(ASCP)SBB Philadelphia, Pennsylvania Patricia Arndt, MT(ASCP)SBB Paul M. Ness, MD Pomona, California Baltimore, Maryland M A N AG I NG E D I TOR James P.
    [Show full text]
  • Current Biomedical Use of Copper Chelation Therapy
    International Journal of Molecular Sciences Review Current Biomedical Use of Copper Chelation Therapy Silvia Baldari 1,2, Giuliana Di Rocco 1 and Gabriele Toietta 1,* 1 Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS Regina Elena National Cancer Institute, via E. Chianesi 53, 00144 Rome, Italy; [email protected] (S.B.); [email protected] (G.D.R.) 2 Department of Medical Surgical Sciences and Biotechnologies, University of Rome “La Sapienza”, C.so della Repubblica 79, 04100 Latina, Italy * Correspondence: [email protected]; Tel.: +39-06-5266-2604 Received: 9 January 2020; Accepted: 4 February 2020; Published: 6 February 2020 Abstract: Copper is an essential microelement that plays an important role in a wide variety of biological processes. Copper concentration has to be finely regulated, as any imbalance in its homeostasis can induce abnormalities. In particular, excess copper plays an important role in the etiopathogenesis of the genetic disease Wilson’s syndrome, in neurological and neurodegenerative pathologies such as Alzheimer’s and Parkinson’s diseases, in idiopathic pulmonary fibrosis, in diabetes, and in several forms of cancer. Copper chelating agents are among the most promising tools to keep copper concentration at physiological levels. In this review, we focus on the most relevant compounds experimentally and clinically evaluated for their ability to counteract copper homeostasis deregulation. In particular, we provide a general overview of the main disorders characterized by a pathological increase in copper levels, summarizing the principal copper chelating therapies adopted in clinical trials. Keywords: copper; chelation therapy; therapeutic chelation; metal homeostasis; cancer; metalloproteins 1.
    [Show full text]
  • Chelation Therapy
    Corporate Medical Policy Chelation Therapy File Name: chelation_therapy Origination: 12/1995 Last CAP Review: 2/2021 Next CAP Review: 2/2022 Last Review: 2/2021 Description of Procedure or Service Chelation therapy is an established treatment for the removal of metal toxins by converting them to a chemically inert form that can be excreted in the urine. Chelation therapy comprises intravenous or oral administration of chelating agents that remove metal ions such as lead, aluminum, mercury, arsenic, zinc, iron, copper, and calcium from the body. Specific chelating agents are used for particular heavy metal toxicities. For example, desferroxamine (not Food and Drug Administration [FDA] approved) is used for patients with iron toxicity, and calcium-ethylenediaminetetraacetic acid (EDTA) is used for patients with lead poisoning. Note that disodium-EDTA is not recommended for acute lead poisoning due to the increased risk of death from hypocalcemia. Another class of chelating agents, called metal protein attenuating compounds (MPACs), is under investigation for the treatment of Alzheimer’s disease, which is associated with the disequilibrium of cerebral metals. Unlike traditional systemic chelators that bind and remove metals from tissues systemically, MPACs have subtle effects on metal homeostasis and abnormal metal interactions. In animal models of Alzheimer’s disease, they promote the solubilization and clearance of β-amyloid protein by binding to its metal-ion complex and also inhibit redox reactions that generate neurotoxic free radicals. MPACs therefore interrupt two putative pathogenic processes of Alzheimer’s disease. However, no MPACs have received FDA approval for treating Alzheimer’s disease. Chelation therapy has also been investigated as a treatment for other indications including atherosclerosis and autism spectrum disorder.
    [Show full text]
  • Review of Oral Iron Chelators (Deferiprone and Deferasirox) for the Treatment of Iron Overload in Pediatric Patients
    Review of Oral Iron Chelators (Deferiprone and Deferasirox) for the Treatment of Iron Overload in Pediatric Patients D. Adam Algren, MD Assistant Professor of Pediatrics and Emergency Medicine Division of Pediatric Pharmacology and Medical Toxicology Departments of Pediatrics and Emergency Medicine Children’s Mercy Hospitals and Clinics/Truman Medical Center University of Missouri-Kansas City School of Medicine 1 PROPOSAL The World Health Organization Model List of Essential Medicines and Model Formulary 2010 list deferoxamine (DFO) as the treatment of choice for both acute and chronic iron poisoning. The Model Formulary currently does not designate any orally administered agents for the chelation of iron. It is proposed that deferasirox be considered the oral chelator of choice in the treatment of chronic iron overload. Deferasirox is widely available recent evidence support that it is both safe and efficacious. INTRODUCTION Acute iron poisoning and chronic iron overload result in significant morbidity and mortality worldwide. Treatment of acute iron poisoning and chronic iron overload can be challenging and care providers are often confronted with management dilemmas. Oral iron supplements are commonly prescribed for patients with iron deficiency anemia. The wide availability of iron supplements and iron-containing multivitamins provide easy accessibility for both adults and children. The approach to treatment of acute iron toxicity involves providing adequate supportive care, optimizing hemodynamic status and antidotal therapy with IV deferoxamine, when indicated.1 Early following an acute ingestion gastrointestinal (GI) decontamination can be potentially beneficial. Multiple options exist including: syrup of ipecac, gastric lavage, and whole bowel irrigation (WBI). Although definitive evidence that GI decontamination decreases morbidity and mortality is lacking it is often considered to be beneficial.
    [Show full text]
  • Chelating Drug Therapy: an Update
    Open Access Austin Journal of Genetics and Genomic Research Review Article Chelating Drug Therapy: An Update Vijay Kumar1, Ashok Kumar2*, Sandeep Kumar Singh1, Manoj Kumar3, Surendra Kumar2, Dinesh Abstract 4 5 Kumar and Ragni Singh Purpose: To study the clinical effects of metal toxicity and current 1Department of Neurology, SGPGIMS, India recommendations for management, including chelation therapy, are reviewed. 2Department of Medical Genetics, SGPGIMS, India 3Department of Microbiology, SGPGIMS, India Summary: Metals are essential to many biological processes, but excess 4Department of Chemistry, Dr. R.M.L. Avadh University, of it becomes hazardous to life. These are necessary for cell growth, electron India transport chain, several enzymatic activities and response of immune systems. 5Bheem Rao Ambedkar Bihar University, India They also serve as a cofactor for several enzymes. Chelation therapy is used for clinical management of the excess of metal. However, each metal requires *Corresponding author: Ashok Kumar, Department a specific chelation agent. A chelate is a compound form between metal and a of Medical Genetics, Sanjay Gandhi Post Graduate compound that contains two or more potential ligands. A promising Fe chelator Institute of Medical Sciences, Lucknow, India is Desferrioxamine (Desferal). Penicillamine and Trientine are uses for copper Received: March 12, 2015; Accepted: April 24, 2015; chelation. Meso-2,3-Dimercaptosuccinic Acid (DMSA) and 2,3-Dimercapto- Published: April 27, 2015 Propanesulphonate (DMPS) can be used as effective chelator of mercury. Dimercaprol, edetate calcium disodium, and succimer are the three agents primarily used for chelation of lead. Conclusion: Metal toxicity remains a significant public health concern. Elimination of elevated metal ions can be achieved by proper chelation agents.
    [Show full text]
  • 3407 M16141436 19 3.Pdf
    Immunohematology JOURNAL OF BLOOD GROUP SEROLOGY AND EDUCATION V OLUME 19, NUMBER 3, 2003 Immunohematology JOURNAL OF BLOOD GROUP SEROLOGY AND EDUCATION V OLUME 19, NUMBER 3, 2003 CONTENTS 73 DNA analysis for donor screening of Dombrock blood group antigens J.R. STORRY, C.M.WESTHOFF,D.CHARLES-PIERRE,M.RIOS,K.HUE-ROYE,S.VEGE,S.NANCE, AND M.E. REID 77 Studies on the Dombrock blood group system in non-human primates C. MOGOS,A.SCHAWALDER,G.R. HALVERSON, AND M.E. REID 83 Murine monoclonal antibodies can be used to type RBCs with a positive DAT G.R. HALVERSON,P.HOWARD,H.MALYSKA,E.TOSSAS, AND M.E. REID 86 Rh antigen and phenotype frequencies and probable genotypes for the four main ethnic groups in Port Harcourt, Nigeria Z.A. JEREMIAH AND F.I. BUSERI 89 Antibodies detected in samples from 21,730 pregnant women S. JOVANOVIC-SRZENTIC,M.DJOKIC,N.TIJANIC,R.DJORDJEVIC,N.RIZVAN,D.PLECAS, AND D. FILIMONOVIC 93 BOOK REVIEWS S. GERALD SANDLER,MD THERESA NESTER,MD 95 COMMUNICATIONS Letter to the Editors Letter From the Editors Irregular RBC antibodies in the Ortho Dedication sera of Brazilian pregnant women 97 IN MEMORIAM BERTIL CEDEGREN,MD 98 99 ANNOUNCEMENTS ADVERTISEMENTS 103 INSTRUCTIONS FOR AUTHORS EDITOR-IN-CHIEF MANAGING EDITOR Delores Mallory, MT(ASCP)SBB Mary H. McGinniss,AB, (ASCP)SBB Rockville, Maryland Bethesda, Maryland TECHNICAL EDITOR SENIOR MEDICAL EDITOR Christine Lomas-Francis, MSc Scott Murphy, MD New York, New York Philadelphia, Pennsylvania ASSOCIATE MEDICAL EDITORS S. Gerald Sandler, MD Geralyn Meny, MD Ralph Vassallo, MD Washington, District of Columbia Philadelphia, Pennsylvania Philadelphia, Pennsylvania EDITORIAL BOARD Patricia Arndt, MT(ASCP)SBB W.
    [Show full text]
  • Study Protocol
    Long-term Safety and Efficacy Study of Deferiprone in Patients with Pantothenate Kinase-Associated Neurodegeneration (PKAN) TIRCON2012V1-EXT CLINICAL STUDY PROTOCOL EudraCT Number: 2014-001427-79 IND Number: 104880 Investigational Product: Deferiprone Development Phase: III Indication Studied: Pantothenate kinase-associated neurodegeneration (PKAN) Study Design: Multi-center, single-arm, open-label, 18-month extension of an earlier 18-month study assessing the safety and efficacy of deferiprone in patients with PKAN Sponsor: ApoPharma Inc. 200 Barmac Drive Toronto, Ontario M9L 2Z7, Canada Telephone: 1-416-749-9300 Toll-Free: 1-800-268-4623 (North America only) Fax: 1-416-401-3867 Sponsor’s Representative: Fernando Tricta, MD Vice President, Medical Affairs Tel: 1-416-401-7332 Fax: 1-416-401-3867 Version and Date of Protocol: Version 2.0, 20 AUG 2014 The information contained in this document is the property of ApoPharma Inc. and is confidential. It may be submitted to a regulatory authority, an ethics committee, or an investigator for the purpose of initiation of a clinical study. Reproduction or disclosure of this information, in whole or in part, is forbidden without the written consent of ApoPharma Inc. ApoPharma Inc. Deferiprone TIRCON2012V1-EXT Clinical Study Protocol v 2.0 SIGNATURE PAGES Sponsor We, the undersigned, hereby declare that this study will be carried out under our supervision in accordance with the methods described herein. Long-term safety and efficacy study of deferiprone in patients Study Title: with pantothenate kinase-associated neurodegeneration (PKAN) Study Code: TIRCON2012V1-EXT Version Number: 2.0 Version Date: 20 AUG 2014 Caroline Fradette, PhD Date (DD MMM YYYY) Director of Clinical Research, ApoPharma Inc.
    [Show full text]